[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

2017-2022 Global and Japan Oral hypoglycemic agents and insulin analogues Market Analysis Report

August 2017 | 128 pages | ID: 2115BB099F3EN
JP Research

US$ 3,085.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Oral hypoglycemic agents and insulin analogues market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Oral hypoglycemic agents and insulin analogues market's development status and future trend in the global and Japan. It splits Oral hypoglycemic agents and insulin analogues market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include
  • ASTRAZENECA AB
  • AUROBINDO PHARMA LTD
  • BAYER HLTHCARE
  • BOEHRINGER INGELHEIM
  • CIPLA LTD
  • DR REDDYS LABS LTD
  • EPIC PHARMA LLC
  • HERITAGE PHARMS INC
  • IMPAX LABS
  • INVAGEN PHARMS
  • JANSSEN PHARMS
  • LABS LLC
  • LUPIN LTD
  • MACLEODS PHARMS LTD
  • MANNKIND
  • MERCK SHARP DOHME
  • MICRO LABS LTD INDIA
  • MYLAN
  • NOVO NORDISK INC
  • PADDOCK LLC
  • PAR PHARM
  • PFIZER
  • SANDOZ
  • SANOFI AVENTIS US
  • SANTARUS INC
  • SB PHARMCO
  • SUN PHARM INDS INC
  • TAKEDA PHARMS USA
  • TEVA
  • APOTEX
Geographically, this report splits the Global market into the following regions:
  • Asia Pacific
    • Japan
      • Tokyo
      • Yokohama
      • Osaka
      • Nagoya
      • Others
    • China
    • Korea
    • India
    • Others
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Russia
    • Others
  • North America
    • United States
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Southeast Asia
    • Singapore
    • Malaysia
    • Vietnam
    • Myanmar
    • Thailand
    • Indonesia
    • Philippines
    • Others
  • Middle East & Africa
    • Saudi Arabia
    • Iran
    • UAE
    • Turkey
    • Israel
    • Egypt
    • South Africa
    • Others
On the basis of product, the Oral hypoglycemic agents and insulin analogues market is primarily split into

Oral hypoglycemic agents and insulin analogues Market, by Insulin sensitizing agents
  • Metformin
  • Buformin
  • Phenformin
  • Pioglitazone
  • Rosiglitazone
  • Troglitazone
  • Aleglitazar
  • Muraglitazar
  • Tesaglitazar
Oral hypoglycemic agents and insulin analogues Market, by Secretagogue
  • Acetohexamide
  • Carbutamide
  • Chlorpropamide
  • Metahexamide
  • Tolazamide
  • Tolbutamide
  • Glibenclamide
  • Glibornuride
  • Glipizide
  • Gliquidone
  • Glisoxepide
  • Glyclopyramide
  • Glimepiride
  • Gliclazide
  • Nateglinide
  • Repaglinide
  • Mitiglinide
  • Exenatide
  • Liraglutide
  • Lixisenatide
  • Linagliptin
  • Saxagliptin
  • Sitagliptin
  • Vildagliptin
Oral hypoglycemic agents and insulin analogues Market, by Insulin Class
  • Insulin Lispro
  • Insulin aspart
  • Glulisine
  • insulin
  • insulin glargine
  • insulin detemir
  • neutral protamine Hagedorn insulin
Oral hypoglycemic agents and insulin analogues Market, byOthers
  • Acarbose
  • Miglitol
  • Voglibose
  • Pramlintide
  • Benfluorex
  • Tolrestat
Key Applications
  • Department of endocrinology
  • Diabetes division
  • Pharmacy
  • Hospital


1 ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES OVERVIEW

1.1 Product Overview and Scope of Oral hypoglycemic agents and insulin analogues
1.2 Global and Japan Oral hypoglycemic agents and insulin analogues Market by Applications/End Users
  1.2.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share Comparison by Applications (2012-2017)
    1.2.1.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Applications (2012-2017)
    1.2.1.2 Japan Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Applications (2012-2017)
    1.2.1.3 Market Drivers and Opportunities
  1.2.2 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share Comparison by Applications (2012-2017)
  1.2.3 Global Oral hypoglycemic agents and insulin analogues Sales by Application (2012-2017)
    1.2.3.1 Global Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Applications (2012-2017)
    1.2.3.2 Global Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Applications (2012-2017)
    1.2.3.3 Market Drivers and Opportunities
  1.2.4 Global Oral hypoglycemic agents and insulin analogues Sales () and Market Share Comparison by Applications (2012-2017)
  1.2.5 Department of endocrinology
  1.2.6 Diabetes division
  1.2.7 Pharmacy
  1.2.8 Hospital
1.3 Global and Japan Market Size (Sales and Revenue) of Oral hypoglycemic agents and insulin analogues (2012-2017)
  1.3.1 Japan Market Size (Sales and Revenue) of Oral hypoglycemic agents and insulin analogues (2012-2017)
    1.3.1.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (%) (2012-2017)
    1.3.1.2 Japan Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate (2012-2017)
  1.3.2 Global Market Size (Sales and Revenue) of Oral hypoglycemic agents and insulin analogues (2012-2017)
    1.3.2.1 Global Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (%) (2012-2017)
    1.3.2.2 Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate (2012-2017)
1.4 Global and Japan Classification of Oral hypoglycemic agents and insulin analogues by Insulin sensitizing agents
  1.4.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Insulin sensitizing agents (2012-2017)
  1.4.2 Global Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Insulin sensitizing agents (2012-2017)
  1.4.3 Japan Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Insulin sensitizing agents (2012-2017)
  1.4.4 Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Insulin sensitizing agents (2012-2017)
  1.4.5 Japan Oral hypoglycemic agents and insulin analogues Price () by Insulin sensitizing agents (2012-2017)
  1.4.6 Global Oral hypoglycemic agents and insulin analogues Price () by Insulin sensitizing agents (2012-2017)
  1.4.7 Japan Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Insulin sensitizing agents (2012-2017)
  1.4.8 Global Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Insulin sensitizing agents (2012-2017)
  1.4.9 Metformin
  1.4.10 Buformin
  1.4.11 Phenformin
  1.4.12 Pioglitazone
  1.4.13 Rosiglitazone
  1.2.8 Tolazamide
  1.2.9 Troglitazone
  1.2.10 Aleglitazar
  1.2.11 Muraglitazar
  1.2.12 Tesaglitazar
1.5 Global and Japan Classification of Oral hypoglycemic agents and insulin analogues by Secretagogue
  1.5.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Secretagogue (2012-2017)
  1.5.2 Global Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Secretagogue (2012-2017)
  1.5.3 Japan Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Secretagogue (2012-2017)
  1.5.4 Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Secretagogue (2012-2017)
  1.5.5 Japan Oral hypoglycemic agents and insulin analogues Price () by Secretagogue (2012-2017)
  1.5.6 Global Oral hypoglycemic agents and insulin analogues Price () by Secretagogue (2012-2017)
  1.5.7 Japan Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Secretagogue (2012-2017)
  1.5.8 Global Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Secretagogue (2012-2017)
  1.5.9 Acetohexamide
  1.5.10 Carbutamide
  1.5.11 Chlorpropamide
  1.5.12 Metahexamide
  1.5.13 Tolazamide
  1.3.9 Tolbutamide
  1.3.10 Glibenclamide
  1.3.11 Glibornuride
  1.3.12 Glipizide
  1.3.13 Gliquidone
  1.3.14 Glisoxepide
  1.3.15 Glyclopyramide
  1.3.16 Glimepiride
  1.3.17 Gliclazide
  1.3.18 Nateglinide
  1.3.19 Repaglinide
  1.3.20 Mitiglinide
  1.3.21 Exenatide
  1.3.22 Liraglutide
  1.3.23 Lixisenatide
  1.3.24 Linagliptin
  1.3.25 Saxagliptin
  1.3.26 Sitagliptin
  1.2.37 Vildagliptin
1.6 Global and Japan Classification of Oral hypoglycemic agents and insulin analogues by Insulin class
  1.6.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Insulin class (2012-2017)
  1.6.2 Global Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Insulin class (2012-2017)
  1.6.3 Japan Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Insulin class (2012-2017)
  1.6.4 Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Insulin class (2012-2017)
  1.6.5 Japan Oral hypoglycemic agents and insulin analogues Price () by Insulin class (2012-2017)
  1.6.6 Global Oral hypoglycemic agents and insulin analogues Price () by Insulin class (2012-2017)
  1.6.7 Japan Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Insulin class (2012-2017)
  1.6.8 Global Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Insulin class (2012-2017)
  1.6.9 Insulin Lispro
  1.6.10 Insulin aspart
  1.6.11 Glulisine
  1.6.12 insulin
  1.6.13 insulin glargine
  1.4.9 neutral protamine Hagedorn insulin
1.7 Global and Japan Classification of Oral hypoglycemic agents and insulin analogues by Others
  1.7.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Others (2012-2017)
  1.7.2 Global Oral hypoglycemic agents and insulin analogues Sales () and Market Share by Others (2012-2017)
  1.7.3 Japan Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Others (2012-2017)
  1.7.4 Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share by Others (2012-2017)
  1.7.5 Japan Oral hypoglycemic agents and insulin analogues Price () by Others (2012-2017)
  1.7.6 Global Oral hypoglycemic agents and insulin analogues Price () by Others (2012-2017)
  1.7.7 Japan Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Others (2012-2017)
  1.7.8 Global Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%) by Others (2012-2017)
  1.7.9 Acarbose
  1.7.10 Miglitol
  1.7.11 Voglibose
  1.7.12 Pramlintide
  1.7.13 Benfluorex
  1.5.9 Tolrestat

2 GLOBAL AND JAPAN ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 Japan Oral hypoglycemic agents and insulin analogues Market Competition by Players/Manufacturers
  2.1.1 Japan Oral hypoglycemic agents and insulin analogues Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.1.2 Japan Oral hypoglycemic agents and insulin analogues Revenue and Share by Players/Manufacturers (2012-2017)
  2.1.3 Japan Oral hypoglycemic agents and insulin analogues Average Price () by Players/Manufacturers (2012-2017)
  2.1.4 Japan Oral hypoglycemic agents and insulin analogues Market Competitive Situation and Trends
    2.1.4.1 Japan Oral hypoglycemic agents and insulin analogues Market Concentration Rate
    2.1.4.2 Japan Oral hypoglycemic agents and insulin analogues Market Share of Top 3 and Top 5 Players/Manufacturers
    2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market
  2.1.5 Japan Players/Manufacturers Oral hypoglycemic agents and insulin analogues Manufacturing Base Distribution, Sales Area, Product Types
2.2 Global Oral hypoglycemic agents and insulin analogues Market Competition by Players/Manufacturers
  2.2.1 Global Oral hypoglycemic agents and insulin analogues Sales and Market Share of Key Players/Manufacturers (2012-2017)
  2.2.2 Global Oral hypoglycemic agents and insulin analogues Revenue and Share by Players/Manufacturers (2012-2017)
  2.2.3 Global Oral hypoglycemic agents and insulin analogues Average Price () by Players/Manufacturers (2012-2017)
  2.2.4 Global Oral hypoglycemic agents and insulin analogues Market Competitive Situation and Trends
    2.2.4.1 Global Oral hypoglycemic agents and insulin analogues Market Concentration Rate
    2.2.4.2 Global Oral hypoglycemic agents and insulin analogues Market Share of Top 3 and Top 5 Players/Manufacturers
    2.2.4.3 Mergers & Acquisitions, Expansion in Global Market
  2.2.5 Global Players/Manufacturers Oral hypoglycemic agents and insulin analogues Manufacturing Base Distribution, Sales Area, Product Types

3 GLOBAL AND JAPAN ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES SALES AND REVENUE BY REGIONS (2012-2017)

3.1 Asia Pacific Oral hypoglycemic agents and insulin analogues Sales and Revenue by Regions (2012-2017)
  3.1.1 Japan Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.1.1.1 Japan Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.1.1.2 Japan Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.1.1.3 Japan Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.1.2 China Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.1.2.1 China Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.1.2.2 China Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.1.2.3 China Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.1.3 Korea Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.1.3.1 Korea Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.1.3.2 Korea Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.1.3.3 Korea Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.1.4 India Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.1.4.1 India Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.1.4.2 India Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.1.4.3 India Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.1.5 Others Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.1.5.1 Others Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.1.5.2 Others Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.1.5.3 Others Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
3.2 Europe Oral hypoglycemic agents and insulin analogues Sales and Revenue by Regions (2012-2017)
  3.2.1 France Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.2.1.1 France Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.2.1.2 France Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.2.1.3 France Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.2.2 Germany Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.2.2.1 Germany Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.2.2.2 Germany Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.2.2.3 Germany Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.2.3 United Kingdom Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.2.3.1 United Kingdom Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.2.3.2 United Kingdom Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.2.3.3 United Kingdom Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.2.4 Italy Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.2.4.1 Italy Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.2.4.2 Italy Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.2.4.3 Italy Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.2.5 Russia Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.2.5.1 Russia Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.2.5.2 Russia Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.2.5.3 Russia Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.2.6 Others Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.2.6.1 Others Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.2.6.2 Others Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.2.6.3 Others Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
3.3 North America Oral hypoglycemic agents and insulin analogues Sales and Revenue by Regions (2012-2017)
  3.3.1 United States Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.3.1.1 United States Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.3.1.2 United States Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.3.1.3 United States Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.3.2 Canada Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.3.2.1 Canada Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.3.2.2 Canada Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.3.2.3 Canada Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
3.4 Latin America Oral hypoglycemic agents and insulin analogues Sales and Revenue by Regions (2012-2017)
  3.4.1 Brazil Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.4.1.1 Brazil Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.4.1.2 Brazil Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.4.1.3 Brazil Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.4.2 Mexico Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.4.2.1 Mexico Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.4.2.2 Mexico Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.4.2.3 Mexico Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.4.3 Others Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.4.3.1 Others Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.4.3.2 Others Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.4.3.3 Others Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
3.5 Southeast Asia Oral hypoglycemic agents and insulin analogues Sales and Revenue by Regions (2012-2017)
  3.5.1 Singapore Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.1.1 Singapore Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.1.2 Singapore Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.1.3 Singapore Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.5.2 Malaysia Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.2.1 Malaysia Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.2.2 Malaysia Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.2.3 Malaysia Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.5.3 Vietnam Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.3.1 Vietnam Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.3.2 Vietnam Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.3.3 Vietnam Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.5.4 Myanmar Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.4.1 Myanmar Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.4.2 Myanmar Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.4.3 Myanmar Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.5.5 Thailand Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.5.1 Thailand Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.5.2 Thailand Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.5.3 Thailand Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.5.6 Indonesia Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.6.1 Indonesia Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.6.2 Indonesia Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.6.3 Indonesia Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.5.7 Philippines Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.7.1 Philippines Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.7.2 Philippines Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.7.3 Philippines Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.5.8 Others Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.5.8.1 Others Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.5.8.2 Others Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.5.8.3 Others Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
3.6 Middle East & Africa Oral hypoglycemic agents and insulin analogues Sales and Revenue by Regions (2012-2017)
  3.6.1 Saudi Arabia Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.1.1 Saudi Arabia Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.1.2 Saudi Arabia Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.1.3 Saudi Arabia Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.6.2 Iran Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.2.1 Iran Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.2.2 Iran Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.2.3 Iran Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.6.3 UAE Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.3.1 UAE Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.3.2 UAE Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.3.3 UAE Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.6.4 Turkey Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.4.1 Turkey Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.4.2 Turkey Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.4.3 Turkey Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.6.5 Israel Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.5.1 Israel Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.5.2 Israel Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.5.3 Israel Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.6.6 Egypt Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.6.1 Egypt Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.6.2 Egypt Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.6.3 Egypt Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.6.7 South Africa Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.7.1 South Africa Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.7.2 South Africa Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.7.3 South Africa Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)
  3.6.8 Others Oral hypoglycemic agents and insulin analogues Sales and Revenue (2012-2017)
    3.6.8.1 Others Oral hypoglycemic agents and insulin analogues Sales () and Market Share (2012-2017)
    3.6.8.2 Others Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Market Share (2012-2017)
    3.6.8.3 Others Oral hypoglycemic agents and insulin analogues Price ()(2012-2017)

4 GLOBAL AND JAPAN ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES PLAYERS/MANUFACTURERS PROFILES AND SALES DATA

4.1 ASTRAZENECA AB
  4.1.1 Company Basic Information, Manufacturing Base and Competitors
  4.1.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.1.2.1 Product A
    4.1.2.2 Product B
  4.1.3 ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.1.4 Main Business/Business Overview
4.2 AUROBINDO PHARMA LTD
  4.2.1 Company Basic Information, Manufacturing Base and Competitors
  4.2.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.2.2.1 Product A
    4.2.2.2 Product B
  4.2.3 AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.2.4 Main Business/Business Overview
4.3 BAYER HLTHCARE
  4.3.1 Company Basic Information, Manufacturing Base and Competitors
  4.3.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.3.2.1 Product A
    4.3.2.2 Product B
  4.3.3 BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.3.4 Main Business/Business Overview
4.4 BOEHRINGER INGELHEIM
  4.4.1 Company Basic Information, Manufacturing Base and Competitors
  4.4.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.4.2.1 Product A
    4.4.2.2 Product B
  4.4.3 BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.4.4 Main Business/Business Overview
4.5 CIPLA LTD
  4.5.1 Company Basic Information, Manufacturing Base and Competitors
  4.5.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.5.2.1 Product A
    4.5.2.2 Product B
  4.5.3 CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.5.4 Main Business/Business Overview
4.6 DR REDDYS LABS LTD
  4.6.1 Company Basic Information, Manufacturing Base and Competitors
  4.6.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.6.2.1 Product A
    4.6.2.2 Product B
  4.6.3 DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.6.4 Main Business/Business Overview
4.7 EPIC PHARMA LLC
  4.7.1 Company Basic Information, Manufacturing Base and Competitors
  4.7.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.7.2.1 Product A
    4.7.2.2 Product B
  4.7.3 EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.7.4 Main Business/Business Overview
4.8 HERITAGE PHARMS INC
  4.8.1 Company Basic Information, Manufacturing Base and Competitors
  4.8.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.8.2.1 Product A
    4.8.2.2 Product B
  4.8.3 HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.8.4 Main Business/Business Overview
4.9 IMPAX LABS
  4.9.1 Company Basic Information, Manufacturing Base and Competitors
  4.9.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.9.2.1 Product A
    4.9.2.2 Product B
  4.9.3 IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.9.4 Main Business/Business Overview
4.10 INVAGEN PHARMS
  4.10.1 Company Basic Information, Manufacturing Base and Competitors
  4.10.2 Oral hypoglycemic agents and insulin analogues Product Category, Application and Specification
    4.10.2.1 Product A
    4.10.2.2 Product B
  4.10.3 INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
  4.10.4 Main Business/Business Overview
4.11 JANSSEN PHARMS
4.12 LABS LLC
4.13 LUPIN LTD
4.14 MACLEODS PHARMS LTD
4.15 MANNKIND
4.16 MERCK SHARP DOHME
4.17 MICRO LABS LTD INDIA
4.18 MYLAN
4.19 NOVO NORDISK INC
4.20 PADDOCK LLC
4.21 PAR PHARM
4.22 PFIZER
4.23 SANDOZ
4.24 SANOFI AVENTIS US
4.25 SANTARUS INC
4.26 SB PHARMCO
4.27 SUN PHARM INDS INC
4.28 TAKEDA PHARMS USA
4.29 TEVA
4.30 APOTEX

5 ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MANUFACTURING COST ANALYSIS

5.1 Oral hypoglycemic agents and insulin analogues Key Raw Materials Analysis
  5.1.1 Key Raw Materials
  5.1.2 Price Trend of Key Raw Materials
  5.1.3 Key Suppliers of Raw Materials
  5.1.4 Market Concentration Rate of Raw Materials
5.2 Proportion of Manufacturing Cost Structure
  5.2.1 Raw Materials
  5.2.2 Labor Cost
  5.2.3 Manufacturing Expenses
5.3 Manufacturing Process Analysis of Oral hypoglycemic agents and insulin analogues

6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

6.1 Oral hypoglycemic agents and insulin analogues Industrial Chain Analysis
6.2 Upstream Raw Materials Sourcing
6.3 Raw Materials Sources of Oral hypoglycemic agents and insulin analogues Major Players/Manufacturers in 2016
6.4 Downstream Buyers

7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

7.1 Marketing Channel
  7.1.1 Direct Marketing
  7.1.2 Indirect Marketing
  7.1.3 Marketing Channel Development Trend
7.2 Market Positioning
  7.2.1 Pricing Strategy
  7.2.2 Brand Strategy
  7.2.3 Target Client
7.3 Distributors/Traders List

8 MARKET EFFECT FACTORS ANALYSIS

8.1 Technology Progress/Risk
  8.1.1 Substitutes Threat
  8.1.2 Technology Progress in Related Industry
8.2 Consumer Needs/Customer Preference Change
8.3 Economic/Political Environmental Change

9 GLOBAL AND JAPAN ORAL HYPOGLYCEMIC AGENTS AND INSULIN ANALOGUES MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

9.1 Global and Japan Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD) Forecast (2017-2022)
9.2 Global and Japan Oral hypoglycemic agents and insulin analogues Sales () Forecast by Type (2017-2022)
  9.2.1 by Insulin sensitizing agents
  9.2.2 by Secretagogue
  9.2.3 by Insulin class
  9.2.4 by Others
9.3 Global and Japan Oral hypoglycemic agents and insulin analogues Sales () Forecast by Application (2017-2022)
9.4 Global and Japan Oral hypoglycemic agents and insulin analogues Sales () Forecast by Regions (2017-2022)

10 RESEARCH FINDINGS AND CONCLUSION

11 METHODOLOGY AND DATA SOURCE

11.1 Methodology/Research Approach
  11.1.1 Research Programs/Design
  11.1.2 Market Size Estimation

LIST OF TABLES AND FIGURES

Figure Product Picture of Oral hypoglycemic agents and insulin analogues
Table Japan Oral hypoglycemic agents and insulin analogues Sales (Million Units) Comparison by Applications (2012-2017)
Figure Japan Sales Market Share (%) of Oral hypoglycemic agents and insulin analogues by Applications in 2016
Table Global Oral hypoglycemic agents and insulin analogues Sales (Million Units) Comparison by Applications (2012-2017)
Figure Global Sales Market Share (%) of Oral hypoglycemic agents and insulin analogues by Applications in 2016
Figure Department of endocrinology Examples
Table Key Downstream Customer in Department of endocrinology
Figure Diabetes division Examples
Table Key Downstream Customer in Diabetes division
Figure Pharmacy Examples
Table Key Downstream Customer in Pharmacy
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Metformin Product Picture
Figure Buformin Product Picture
Figure Phenformin Product Picture
Figure Pioglitazone Product Picture
Figure Rosiglitazone Product Picture
Figure Acetohexamide Product Picture
Figure Carbutamide Product Picture
Figure Chlorpropamide Product Picture
Figure Metahexamide Product Picture
Figure Tolazamide Product Picture
Figure Insulin Lispro Product Picture
Figure Insulin aspart Product Picture
Figure Glulisine Product Picture
Figure insulin Product Picture
Figure insulin glargine Product Picture
Figure Acarbose Product Picture
Figure Miglitol Product Picture
Figure Voglibose Product Picture
Figure Pramlintide Product Picture
Figure Benfluorex Product Picture
Table ASTRAZENECA AB Basic Information List
Table ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure ASTRAZENECA AB Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table AUROBINDO PHARMA LTD Basic Information List
Table AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure AUROBINDO PHARMA LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table BAYER HLTHCARE Basic Information List
Table BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure BAYER HLTHCARE Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table BOEHRINGER INGELHEIM Basic Information List
Table BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure BOEHRINGER INGELHEIM Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table CIPLA LTD Basic Information List
Table CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table CIPLA LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure CIPLA LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table DR REDDYS LABS LTD Basic Information List
Table DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure DR REDDYS LABS LTD Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table EPIC PHARMA LLC Basic Information List
Table EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure EPIC PHARMA LLC Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table HERITAGE PHARMS INC Basic Information List
Table HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure HERITAGE PHARMS INC Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table IMPAX LABS Basic Information List
Table IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table IMPAX LABS Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure IMPAX LABS Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table INVAGEN PHARMS Basic Information List
Table INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)
Table INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Growth Rate (%)(2012-2017)
Table INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Sales Market Share (%) in Japan (2012-2017)
Figure INVAGEN PHARMS Oral hypoglycemic agents and insulin analogues Revenue Market Share (%) in Japan (2012-2017)
Table JANSSEN PHARMS Basic Information List
Table LABS LLC Basic Information List
Table LUPIN LTD Basic Information List
Table MACLEODS PHARMS LTD Basic Information List
Table MANNKIND Basic Information List
Table MERCK SHARP DOHME Basic Information List
Table MICRO LABS LTD INDIA Basic Information List
Table MYLAN Basic Information List
Table NOVO NORDISK INC Basic Information List
Table PADDOCK LLC Basic Information List
Table PAR PHARM Basic Information List
Table PFIZER Basic Information List
Table SANDOZ Basic Information List
Table SANOFI AVENTIS US Basic Information List
Table SANTARUS INC Basic Information List
Table SB PHARMCO Basic Information List
Table SUN PHARM INDS INC Basic Information List
Table TAKEDA PHARMS USA Basic Information List
Table TEVA Basic Information List
Table APOTEX Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Oral hypoglycemic agents and insulin analogues
Figure Manufacturing Process Analysis of Oral hypoglycemic agents and insulin analogues
Figure Oral hypoglycemic agents and insulin analogues Industrial Chain Analysis
Table Raw Materials Sources of Oral hypoglycemic agents and insulin analogues Major Players/Manufacturers in 2016
Table Major Buyers of Oral hypoglycemic agents and insulin analogues
Table Distributors/Traders List
Figure Japan Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Japan Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Japan Oral hypoglycemic agents and insulin analogues Price () Trend Forecast (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales () and Growth Rate (%) Forecast (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Price () Trend Forecast (2017-2022)
Table Japan Oral hypoglycemic agents and insulin analogues Sales () Forecast by Type (2017-2022)
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Type (2017-2022)
Figure Japan Oral hypoglycemic agents and insulin analogues Sales () Forecast by Type (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Type (2017-2022)
Figure Japan Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Type in 2017
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Type in 2017
Table Japan Oral hypoglycemic agents and insulin analogues Sales () Forecast by Application (2017-2022)
Figure Japan Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Application (2017-2022)
Figure Japan Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Application in 2017
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Application (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Application (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Market Share Forecast by Application in 2017
Table Japan Oral hypoglycemic agents and insulin analogues Sales () Forecast by Regions (2017-2022)
Table Japan Oral hypoglycemic agents and insulin analogues Sales Volume Share Forecast by Regions (2017-2022)
Figure Japan Oral hypoglycemic agents and insulin analogues Sales Volume Share Forecast by Regions (2017-2022)
Table Global Oral hypoglycemic agents and insulin analogues Sales () Forecast by Regions (2017-2022)
Table Global Oral hypoglycemic agents and insulin analogues Sales Volume Share Forecast by Regions (2017-2022)
Figure Global Oral hypoglycemic agents and insulin analogues Sales Volume Share Forecast by Regions (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories